vestnik-bio-msuВестник Московского университета. Серия 16. БиологияVestnik Moskovskogo universiteta. Seriya 16. Biologiya0137-0952Lomonosov Moscow State University, School of Biology10.55959/MSU0137-0952-16-79-4-10vestnik-bio-msu-1440Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯRESEARCH ARTICLESГель-электрофорез как метод классификации ингибиторов поли(АДФ-рибоза)-полимераз 1 и 2Gel electrophoretic analysis of protein-DNA complexes to classify inhibitors of poly(ADP-ribose) polymerases 1 and 2ЛобановаА. А.LobanovaA. A.

Лобанова Ангелина Андреевна – инженер, магистр 1 года кафедры  

119234, г. Москва, Ленинские горы, д. 1, стр. 12, Тел.: 8-495-939-57-38

Lenin Hills 1, bldg. 12, Moscow, 119234 

angelina.lobanova@student.msu.ruКоровинаА. Н.KorovinaA. N.

Коровина Анна Николаевна – науч. сотр. кафедры 

119234, г. Москва, Ленинские горы, д. 1, стр. 12, Тел.: 8-495-939-57-38 

Lenin Hills 1, bldg. 12, Moscow, 119234 

anna.korovina@gmail.comКошкинаД. О.KoshkinaD. O.

Кошкина Дарья Олеговна – мл. науч. сотр. кафедры 

119234, г. Москва, Ленинские горы, д. 1, стр. 12, Тел.: 8-495-939-57-38 

Lenin Hills 1, bldg. 12, Moscow, 119234 

koshkina.daria.2015@post.bio.msu.ruЧерниковаП. А.ChernikovaP. A.

Черникова Полина Андреевна – мл. науч. сотр. кафедры 

119234, г. Москва, Ленинские горы, д. 1, стр. 12, Тел.: 8-495-939-57-38 

Lenin Hills 1, bldg. 12, Moscow, 119234 

xirom210197@gmail.comhttps://orcid.org/0000-0002-1596-9506ФеофановА. В.FeofanovA. V.

Феофанов Алексей Валерьевич – докт. биол. наук, руководитель лаборатории оптической микроскопии и спектроскопии биомолекул ИБХ РАН, проф. кафедры

119234, г. Москва, Ленинские горы, д. 1, стр. 12,  Тел.: 8-495-938-22-91 

Lenin Hills 1, bldg. 12, Moscow, 119234 

avfeofanov@yandex.ruhttps://orcid.org/0000-0002-7389-7993СтудитскийВ. М.StuditskyV. M.

Студитский Василий Михайлович – докт. биол. наук, гл. науч. сотр. Кафедры и отдела эпигенетики рака ракового центра

119234, г. Москва, Ленинские горы, д. 1, стр. 12,  Тел.: 8-495-938-22-91 

США, штат Филадельфия, 19111-2497, г. Филадельфия, Коттман Авеню, д. 333 

Lenin Hills 1, bldg. 12, Moscow, 119234 

Cottman Avenue 333, Philadelphia, Philadelphia 19111-2497, USA 

vasily.studitsky@fccc.eduhttps://orcid.org/0000-0002-5067-7939НиловД. К.NilovD. K.

Нилов Дмитрий Константинович – вед. науч. сотр.отдела биокинетики 

19992, Москва, Ленинские горы, д. 1, стр. 40, Тел.: 8-495-939-53-59

Lenin Hills 1, bldg. 40, 119992 

nilovdm@gmail.comhttps://orcid.org/0000-0003-4129-4984МалюченкоН. В.MaluchenkoN. V.

Малюченко Наталия Валериевна – канд. биол. наук, доц. кафедры 

119234, г. Москва, Ленинские горы, д. 1, стр. 12, Тел.: 8-495-939-57-38 

Lenin Hills 1, bldg. 12, Moscow, 119234 

mal_nat@mail.ruКафедра биоинженерии, биологический факультет, Московский государственный университет имени М.В. ЛомоносоваРоссияDepartment of Bioengineering, School of Biology, Lomonosov Moscow State UniversityRussian FederationКафедра биоинженерии, биологический факультет, Московский государственный университет имени М.В. Ломоносова ; Центр исследований рака Фокс ЧейзРоссияDepartment of Bioengineering, School of Biology, Lomonosov Moscow State University ; Fox Chase Cancer Research CenterRussian FederationНаучно-исследовательский институт физико-химической биологии имени А.Н. Белозерского, Московский государственный университет имени М.В. ЛомоносоваРоссияBelozersky Institute of Physicochemical Biology, Lomonosov Moscow State UniversityRussian Federation202403032025794322329Copyright © Лобанова А.А., Коровина А.Н., Кошкина Д.О., Черникова П.А., Феофанов А.В., Студитский В.М., Нилов Д.К., Малюченко Н.В., 20252025Лобанова А.А., Коровина А.Н., Кошкина Д.О., Черникова П.А., Феофанов А.В., Студитский В.М., Нилов Д.К., Малюченко Н.В.Lobanova A.A., Korovina A.N., Koshkina D.O., Chernikova P.A., Feofanov A.V., Studitsky V.M., Nilov D.K., Maluchenko N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik-bio-msu.elpub.ru/jour/article/view/1440

Поли(АДФ-рибоза)-полимеразы 1 и 2 (PARP1 и PARP2) играют важную роль в репарации повреждений ДНК в клетке, а их ингибирование применяется для лечения некоторых онкологических заболеваний. Ведутся активные разработки новых ингибиторов PARP и изучение механизмов их действия. В настоящей работе на примере ингибиторов талазопариба, олапариба и велипариба показано, что электрофорез в полиакриламидном геле комплексов ДНК с PARP1 и PARP2 в присутствии ингибиторов позволяет выявить их влияние на сродство ферментов к ДНК, а после добавления субстрата НАД+ – оценить эффективность ингибирования каталитической активности ферментов. Учет данных механизмов действия важен для поиска новых ингибиторов PARP1 и PARP2.

Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2) play an important role in repairing DNA, and their inhibition is being used to treat certain oncological diseases. New inhibitors of PARP are being actively developed and the mechanisms of their action are being studied. In the present work, using the inhibitors talazoparib, olaparib and veliparib, as example, it is shown that electrophoresis of DNA complexes with PARP1 and PARP2 in polyacrylamide gel in the presence of inhibitors makes it possible to identify the effect of inhibitors on the affinity of enzymes to DNA, and after adding the NAD+ substrate, to evaluate the inhibition of the catalytic activity of enzymes. When selecting new inhibitors for biomedical research, it is important to consider these mechanisms of action against PARP1 and PARP2.

PARPингибиторыэлектрофорезталазопариболапарибвелипарибPARPinhibitorselectrophoresistalazoparibolaparibveliparibРабота поддержана в рамках Междисциплинарных научно-образовательных школ Московского государственного университета (проект № 23-Ш04-57; исследование ингибиторов методом гель-электрофореза), а также Российским научным фондом (проект № 19-74-30003; экспрессия и очистка белков PARP1 и PARP2).The study was supported by the scientific project of Lomonosov Moscow State University research and education schools (project No. 23-Sh04-57; study of inhibitors by gel electrophoresis) and by the Russian Science Foundation (project No. 19-74-30003; expression and purification of PARP1 and PARP2 proteins).ReferencesLangelier M.F., Eisemann T., Riccio A.A., Pascal J.M. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr. Opin. Struct. Biol. 2018;53:187–198.Langelier M.F., Eisemann T., Riccio A.A., Pascal J.M. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr. Opin. Struct. Biol. 2018;53:187–198.Szanto M., Yelamos J., Bai P. Specific and shared biological functions of PARP2 – is PARP2 really a lil’ brother of PARP1? Expert. Rev. Mol. Med. 2024;3(26)e13.Szanto M., Yelamos J., Bai P. Specific and shared biological functions of PARP2 – is PARP2 really a lil’ brother of PARP1? Expert. Rev. Mol. Med. 2024;3(26)e13.Kutuzov M.M., Belousova E.A., Ilina E.S., Lavrik O.I. Impact of PARP1, PARP2 & PARP3 on the base excision repair of nucleosomal DNA. Mechanisms of genome protection and repair. Advances in experimental medicine and biology, vol 1241. Ed. D. Zharkov. Cham Springer, 2020:47–57.Kutuzov M.M., Belousova E.A., Ilina E.S., Lavrik O.I. Impact of PARP1, PARP2 & PARP3 on the base excision repair of nucleosomal DNA. Mechanisms of genome protection and repair. Advances in experimental medicine and biology, vol 1241. Ed. D. Zharkov. Cham Springer, 2020:47–57.Alemasova E.E., Lavrik O.I. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res. 2019;47(8):3811–3827.Alemasova E.E., Lavrik O.I. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res. 2019;47(8):3811–3827.Cohen M.S., Chang P. Insights into the biogenesis, function, and regulation of ADP-ribosylation. Nat. Chem. Biol. 2018;14(3):236–243.Cohen M.S., Chang P. Insights into the biogenesis, function, and regulation of ADP-ribosylation. Nat. Chem. Biol. 2018;14(3):236–243.Maluchenko N.V., Koshkina D.O., Feofanov A.V., Studitsky V.M., Kirpichnikov M.P. Poly(ADP-ribosyl) code functions. Acta Naturae. 2021;13(2):58–69.Maluchenko N.V., Koshkina D.O., Feofanov A.V., Studitsky V.M., Kirpichnikov M.P. Poly(ADP-ribosyl) code functions. Acta Naturae. 2021;13(2):58–69.Pan L., Penney J., Tsai L.H. Chromatin regulation of DNA damage repair and genome integrity in the central nervous system. J. Mol. Biol. 2014;426(20):3376–3388.Pan L., Penney J., Tsai L.H. Chromatin regulation of DNA damage repair and genome integrity in the central nervous system. J. Mol. Biol. 2014;426(20):3376–3388.Ko H.L., Ren E.C. Functional aspects of PARP1 in DNA repair and transcription. Biomolecules. 2012:2(4):524–548.Ko H.L., Ren E.C. Functional aspects of PARP1 in DNA repair and transcription. Biomolecules. 2012:2(4):524–548.Das B., Choudhury B., Kumar A., Jyoti Baruah V. Genomic instability and DNA repair in cancer. DNA: Damages and repair mechanisms. Ed. P. Behzadi. IntechOpen; 2021:189–202.Das B., Choudhury B., Kumar A., Jyoti Baruah V. Genomic instability and DNA repair in cancer. DNA: Damages and repair mechanisms. Ed. P. Behzadi. IntechOpen; 2021:189–202.Pazzaglia S., Pioli C. Multifaceted role of PARP-1 in DNA repair and inflammation: Pathological and therapeutic implications in cancer and non-cancer diseases. Cells. 2019;9(1):41.Pazzaglia S., Pioli C. Multifaceted role of PARP-1 in DNA repair and inflammation: Pathological and therapeutic implications in cancer and non-cancer diseases. Cells. 2019;9(1):41.Frederick M.I., Abdesselam D., Clouvel A., Croteau L., Hassan S. Leveraging PARP-1/2 to target distant metastasis. Int. J. Mol. Sci. 2024;25(16):9032.Frederick M.I., Abdesselam D., Clouvel A., Croteau L., Hassan S. Leveraging PARP-1/2 to target distant metastasis. Int. J. Mol. Sci. 2024;25(16):9032.Spiegel J.O., Van Houten B., Durrant J.D. PARP1: structural insights and pharmacological targets for inhibition. DNA Repair (Amst.). 2021;103:103125.Spiegel J.O., Van Houten B., Durrant J.D. PARP1: structural insights and pharmacological targets for inhibition. DNA Repair (Amst.). 2021;103:103125.Zandarashvili L., Langelier M.F., Velagapudi U.K., Hancock M.A., Steffen J.D., Billur R., Hannan Z.M., Wicks A.J., Krastev D.B., Pettitt S.J., Lord C.J., Talele T.T., Pascal J.M., Black B.E. Structural basis for allosteric PARP-1 retention on DNA breaks. Science. 2020;368(6486):eaax6367.Zandarashvili L., Langelier M.F., Velagapudi U.K., Hancock M.A., Steffen J.D., Billur R., Hannan Z.M., Wicks A.J., Krastev D.B., Pettitt S.J., Lord C.J., Talele T.T., Pascal J.M., Black B.E. Structural basis for allosteric PARP-1 retention on DNA breaks. Science. 2020;368(6486):eaax6367.Langelier M.F., Lin X., Zha S., Pascal J.M.. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. Sci. Adv. 2023;9(12):eadf7175.8.Langelier M.F., Lin X., Zha S., Pascal J.M.. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. Sci. Adv. 2023;9(12):eadf7175.8.Rudolph J., Jung K., Luger K. Inhibitors of PARP: number crunching and structure gazing. Proc. Natl. Acad. Sci. U.S.A. 2022;119(11):e2121979119.Rudolph J., Jung K., Luger K. Inhibitors of PARP: number crunching and structure gazing. Proc. Natl. Acad. Sci. U.S.A. 2022;119(11):e2121979119.Malyuchenko N.V., Kotova E.Y., Kulaeva O.I., Kirpichnikov M.P., Studitsky V.M. PARP1 Inhibitors: antitumor drug design. Acta Naturae. 2015;7(3):27–37.Malyuchenko N.V., Kotova E.Y., Kulaeva O.I., Kirpichnikov M.P., Studitsky V.M. PARP1 Inhibitors: antitumor drug design. Acta Naturae. 2015;7(3):27–37.Velagapudi U.K., Langelier M.F., Delgado-Martin C., Diolaiti M.E., Bakker S., Ashworth A., Patel B.A., Shao X., Pascal J.M., Talele T.T. Design and synthesis of poly(ADP-ribose) polymerase inhibitors: impact of adenosine pocket-binding motif appendage to the 3-oxo-2,3-dihydrobenzofuran-7-carboxamide on potency and selectivity. J. Med. Chem. 2019;62(11):5330–5357.Velagapudi U.K., Langelier M.F., Delgado-Martin C., Diolaiti M.E., Bakker S., Ashworth A., Patel B.A., Shao X., Pascal J.M., Talele T.T. Design and synthesis of poly(ADP-ribose) polymerase inhibitors: impact of adenosine pocket-binding motif appendage to the 3-oxo-2,3-dihydrobenzofuran-7-carboxamide on potency and selectivity. J. Med. Chem. 2019;62(11):5330–5357.Kaufman B., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., Balmaña J., Mitchell G., Fried G., Stemmer S.M., Hubert A., Rosengarten O., Steiner M., Loman N., Bowen K., Fielding A., Domchek S.M. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 2015;33(3):244–250.Kaufman B., Shapira-Frommer R., Schmutzler R.K., Audeh M.W., Friedlander M., Balmaña J., Mitchell G., Fried G., Stemmer S.M., Hubert A., Rosengarten O., Steiner M., Loman N., Bowen K., Fielding A., Domchek S.M. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 2015;33(3):244–250.Harvey-Jones E., Raghunandan M., RobbezMasson L., et al. Longitudinal profiling identifies cooccurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann. Oncol. 2024;35(4):364–380.Harvey-Jones E., Raghunandan M., RobbezMasson L., et al. Longitudinal profiling identifies cooccurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann. Oncol. 2024;35(4):364–380.Murthy P., Muggia F. PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resist. 2019;2(3):665–679.Murthy P., Muggia F. PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resist. 2019;2(3):665–679.Bruin M.A.C., Sonke G.S., Beijnen J.H., Huitema A.D.R. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin. Pharmacokinet. 2022;61(12):1649–1675.Bruin M.A.C., Sonke G.S., Beijnen J.H., Huitema A.D.R. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin. Pharmacokinet. 2022;61(12):1649–1675.Loehr A., Hussain A., Patnaik A., Bryce A.H., et al. Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib. Eur. Urol. 2023;83(3):200–209.Loehr A., Hussain A., Patnaik A., Bryce A.H., et al. Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib. Eur. Urol. 2023;83(3):200–209.Maluchenko N., Koshkina D., Korovina A., Studitsky V., Feofanov A. Interactions of PARP1 inhibitors with PARP1-nucleosome complexes. Cells. 2022;11(21):3343.Maluchenko N., Koshkina D., Korovina A., Studitsky V., Feofanov A. Interactions of PARP1 inhibitors with PARP1-nucleosome complexes. Cells. 2022;11(21):3343.Kutuzov M.M., Khodyreva S.N., Ame J.C., Ilina E.S., Sukhanova M.V., Schreiber V., Lavrik O.I. Interaction of PARP-2 with DNA structures mimicking DNA repair intermediates and consequences on activity of base excision repair proteins. Biochimie. 2013;95(6):1208–1215.Kutuzov M.M., Khodyreva S.N., Ame J.C., Ilina E.S., Sukhanova M.V., Schreiber V., Lavrik O.I. Interaction of PARP-2 with DNA structures mimicking DNA repair intermediates and consequences on activity of base excision repair proteins. Biochimie. 2013;95(6):1208–1215.Deeksha W., Abhishek S., Giri J., Rajakumara E. Regulation of PARP1 and its apoptotic variant activity by single-stranded DNA. FEBS J. 2023; 290(18):4533–4542.Deeksha W., Abhishek S., Giri J., Rajakumara E. Regulation of PARP1 and its apoptotic variant activity by single-stranded DNA. FEBS J. 2023; 290(18):4533–4542.Laspata N., Kaur P., Mersaoui S.Y., Muoio D., Liu Z.S., Bannister M.H., Nguyen H.D., Curry C., Pascal J.M., Poirier G.G., Wang H., Masson J.Y., Fouquerel E. PARP1 associates with R-loops to promote their resolution and genome stability. Nucleic Acids Res. 2023;51(5):2215–2237.Laspata N., Kaur P., Mersaoui S.Y., Muoio D., Liu Z.S., Bannister M.H., Nguyen H.D., Curry C., Pascal J.M., Poirier G.G., Wang H., Masson J.Y., Fouquerel E. PARP1 associates with R-loops to promote their resolution and genome stability. Nucleic Acids Res. 2023;51(5):2215–2237.Andreeva T.V., Maluchenko N.V., Efremenko A.V., Lyubitelev A.V., Korovina A.N., Afonin D.A., Kirpichnikov M.P., Studitsky V.M., Feofanov A.V. Epigallocatechin gallate affects the structure of chromatosomes, nucleosomes and their complexes with PARP1. Int. J. Mol. Sci. 2023;24(18):14187.Andreeva T.V., Maluchenko N.V., Efremenko A.V., Lyubitelev A.V., Korovina A.N., Afonin D.A., Kirpichnikov M.P., Studitsky V.M., Feofanov A.V. Epigallocatechin gallate affects the structure of chromatosomes, nucleosomes and their complexes with PARP1. Int. J. Mol. Sci. 2023;24(18):14187.Langelier M.F., Steffen J.D., Riccio A.A., McCauley M., Pascal J.M. Purification of DNA damage-dependent PARPs from E. coli for structural and biochemical analysis. Poly(ADP-Ribose) Polymerase. Methods in Molecular Biology, vol 1608. Ed. A. Tulin. N.Y.: Humana Press, 2017: 431–444.Langelier M.F., Steffen J.D., Riccio A.A., McCauley M., Pascal J.M. Purification of DNA damage-dependent PARPs from E. coli for structural and biochemical analysis. Poly(ADP-Ribose) Polymerase. Methods in Molecular Biology, vol 1608. Ed. A. Tulin. N.Y.: Humana Press, 2017: 431–444.Maluchenko N., Saulina A., Geraskina O., Kotova E., Korovina A., Feofanov A., Studitsky V. Zinc-dependent nucleosome reorganization by PARP2. bioRxiv. 2023.Maluchenko N., Saulina A., Geraskina O., Kotova E., Korovina A., Feofanov A., Studitsky V. Zinc-dependent nucleosome reorganization by PARP2. bioRxiv. 2023.Maluchenko N.V., Nilov D.K., Pushkarev S.V., Kotova E.Y., Gerasimova N.S., Kirpichnikov M.P., Langelier M.F., Pascal J.M., Akhtar M.S., Feofanov A.V., Studitsky V.M. Mechanisms of nucleosome reorganization by PARP1. Int. J. Mol. Sci. 2021;22(22):12127.Maluchenko N.V., Nilov D.K., Pushkarev S.V., Kotova E.Y., Gerasimova N.S., Kirpichnikov M.P., Langelier M.F., Pascal J.M., Akhtar M.S., Feofanov A.V., Studitsky V.M. Mechanisms of nucleosome reorganization by PARP1. Int. J. Mol. Sci. 2021;22(22):12127.Chappidi N., Quail T., Doll S., Vogel L.T., Aleksandrov R., Felekyan S., Kuhnemuth R., Stoynov S., Seidel C.A.M., Brugues J., Jahnel M., Franzmann T.M., Alberti S. PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends. Cell. 2024;187(4):945-961.e18.Chappidi N., Quail T., Doll S., Vogel L.T., Aleksandrov R., Felekyan S., Kuhnemuth R., Stoynov S., Seidel C.A.M., Brugues J., Jahnel M., Franzmann T.M., Alberti S. PARP1-DNA co-condensation drives DNA repair site assembly to prevent disjunction of broken DNA ends. Cell. 2024;187(4):945-961.e18.Vasil’eva I., Moor N., Anarbaev R., Kutuzov M., Lavrik O. Functional roles of PARP2 in assembling proteinprotein complexes involved in base excision DNA repair. Int. J. Mol. Sci. 2021;22(9):4679.Vasil’eva I., Moor N., Anarbaev R., Kutuzov M., Lavrik O. Functional roles of PARP2 in assembling proteinprotein complexes involved in base excision DNA repair. Int. J. Mol. Sci. 2021;22(9):4679.Murai J., Huang S.Y., Das B.B., Renaud A., Zhang Y., Doroshow J.H., Ji J., Takeda S., Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599.Murai J., Huang S.Y., Das B.B., Renaud A., Zhang Y., Doroshow J.H., Ji J., Takeda S., Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599.Murai J. Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int. J. Clin. Oncol. 2017;22:619–628.Murai J. Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int. J. Clin. Oncol. 2017;22:619–628.Murai J., Huang S.Y., Renaud A., Zhang Y., Ji J., Takeda S., Morris J., Teicher B., Doroshow J.H., Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 2014;13(2):433–443.Murai J., Huang S.Y., Renaud A., Zhang Y., Ji J., Takeda S., Morris J., Teicher B., Doroshow J.H., Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 2014;13(2):433–443.

The authors declare that there are no conflicts of interest present.